HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Concerns exist for off-label ESA indications
-
- Is a Risk Evaluation and Mitigation Strategy necessary for erythropoiesis-stimulating agents? Meir Wetzler, MD; Craig M. Kessler, MD
- REMS for ESAs: The FDA mandated program is under scrutiny
- RE-NOVATE II: Dabigatran superior to enoxaparin after total hip replacement
- Extranodal natural killer/T-cell lymphoma, nasal type, in a 50-year-old black man Luqman Dad, MD
- Maximum tolerated exposure: A more rational approach to drug dosing Salvatore J. Salamone, PhD; Joseph R. Bertino, MD
- Pleomorphic liposarcoma of the thigh Munir Ghesani, MD, FACNM; Irene Dy, MD; Neil Gupta, MD
- Bone marrow, mobilized blood cells yield similar long-term outcomes after transplant
- Cervical cancer screening may be done too frequently in low-risk women
-
- Dose-dense chemotherapy combined with dual HER-2 targeting agents not feasible
- Laparoscopic surgery for rectal cancer feasible; may not be appropriate for routine use
- Loss of the Y chromosome in Ph+CML patients predicted poor response to imatinib
- Obesity associated with poorer prognosis in women with early stage breast cancer
- Risk for nonsentinel node metastases increased with size of sentinel node metastasis
- EORTC 30986: Gemcitabine/carboplatin did not improve survival in advanced urothelial cancer
- What hope means to patients Christine A. Zawistowski, MD